Upstate Active Clinical Trials
Study Title:A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
What is the purpose of the study?Treatment study to improve cure rate for AML by adding bortezomib, to the standard chemotherapy regimen, to find out the dose and effectiveness of sorafenib & to better understand the biology of AML better.
Upstate Institutional Review Board (IRB) Number:253382
Patient Age Group:Children
Principal Investigator:Melanie A Comito
Who can I contact for more information?
Name: Beatriz Kovar